-- O3 Mining Brief: National Bank Thesis "Heightened Given recent proposed integration in the district"-August 2024-www.financetom.com

-- O3 Mining Brief: National Bank Thesis "Heightened Given recent proposed integration in the district"

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

-- O3 Mining Brief: National Bank Thesis "Heightened Given recent proposed integration in the district"

Aug 14, 2024 7:19 AM

09:51 AM EDT, 08/14/2024 (MT Newswires) --

Price: 1.08, Change: -0.08, Percent Change: -6.90

Previous page： -- O3 Mining Brief: National Bank Thesis based on prospective exploration upside in a Tier 1 jurisdiction, with M&A appeal given Marban's Near 2.6 mln oz in an operating mining jurisdiction Next page： DexCom's Glucose Monitoring System Available for Insurance Coverage in Quebec

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

-- O3 Mining Brief: National Bank Thesis based on prospective exploration upside in a Tier 1 jurisdiction, with M&A appeal given Marban's Near 2.6 mln oz in an operating mining jurisdiction

Aug 14, 2024

09:50 AM EDT, 08/14/2024 (MT Newswires) -- Price: 1.08, Change: -0.08, Percent Change: -6.90 ...

DexCom's Glucose Monitoring System Available for Insurance Coverage in Quebec

Aug 14, 2024

09:50 AM EDT, 08/14/2024 (MT Newswires) -- DexCom ( DXCM ) said Wednesday that its Dexcom G7 Continuous Glucose Monitoring System will be added to the Regie de l'assurance maladie du Quebec's Public Prescription Drug Insurance Plan. As a result, eligible type 1 diabetes patients will be able to receive coverage for Dexcom G7, the company said. Shares of DexCom...

-- O3 Mining Brief: National Bank Thesis "Heightened Given recent proposed integration in the district"

Aug 14, 2024

09:51 AM EDT, 08/14/2024 (MT Newswires) -- Price: 1.08, Change: -0.08, Percent Change: -6.90 ...

Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?

Aug 14, 2024

On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. ( VRCA ) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to...